147 related articles for article (PubMed ID: 17449173)
1. Gene expression and promoter methylation of the XIAP-associated Factor 1 in renal cell carcinomas: correlations with pathology and outcome.
Kempkensteffen C; Hinz S; Schrader M; Christoph F; Magheli A; Krause H; Schostak M; Miller K; Weikert S
Cancer Lett; 2007 Sep; 254(2):227-35. PubMed ID: 17449173
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas.
Byun DS; Cho K; Ryu BK; Lee MG; Kang MJ; Kim HR; Chi SG
Cancer Res; 2003 Nov; 63(21):7068-75. PubMed ID: 14612497
[TBL] [Abstract][Full Text] [Related]
4. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Christoph F; Hinz S; Kempkensteffen C; Schostak M; Schrader M; Miller K
J Urol; 2007 Dec; 178(6):2655-9. PubMed ID: 17945286
[TBL] [Abstract][Full Text] [Related]
5. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses.
Lee MG; Huh JS; Chung SK; Lee JH; Byun DS; Ryu BK; Kang MJ; Chae KS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Oncogene; 2006 Sep; 25(42):5807-22. PubMed ID: 16909101
[TBL] [Abstract][Full Text] [Related]
6. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
7. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-beta.
Micali OC; Cheung HH; Plenchette S; Hurley SL; Liston P; LaCasse EC; Korneluk RG
BMC Cancer; 2007 Mar; 7():52. PubMed ID: 17376236
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
9. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
10. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
11. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
Shibata T; Mahotka C; Wethkamp N; Heikaus S; Gabbert HE; Ramp U
Diagn Mol Pathol; 2007 Mar; 16(1):1-8. PubMed ID: 17471152
[TBL] [Abstract][Full Text] [Related]
12. hTERT expression in sporadic renal cell carcinomas.
Paradis V; Bièche I; Dargère D; Bonvoust F; Ferlicot S; Olivi M; Lagha NB; Blanchet P; Benoît G; Vidaud M; Bedossa P
J Pathol; 2001 Sep; 195(2):209-17. PubMed ID: 11592100
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
14. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma.
Cho M; Uemura H; Kim SC; Kawada Y; Yoshida K; Hirao Y; Konishi N; Saga S; Yoshikawa K
Br J Cancer; 2001 Aug; 85(4):563-7. PubMed ID: 11506497
[TBL] [Abstract][Full Text] [Related]
16. Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1.
Sun Y; Qiao L; Xia HH; Lin MC; Zou B; Yuan Y; Zhu S; Gu Q; Cheung TK; Kung HF; Yuen MF; Chan AO; Wong BC
Cancer Lett; 2008 Feb; 260(1-2):62-71. PubMed ID: 18035482
[TBL] [Abstract][Full Text] [Related]
17. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Chen G; Wang Y; Huang H; Lin F; Wu D; Sun A; Chang H; Feng Y
Eur J Haematol; 2009 Mar; 82(3):176-83. PubMed ID: 19077051
[TBL] [Abstract][Full Text] [Related]
18. Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses.
Chung SK; Lee MG; Ryu BK; Lee JH; Han J; Byun DS; Chae KS; Lee KY; Jang JY; Kim HJ; Chi SG
Gastroenterology; 2007 Jun; 132(7):2459-77. PubMed ID: 17570219
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
[TBL] [Abstract][Full Text] [Related]
20. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
